Proteins and Peptides

10 Dec 2019 BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors
10 Dec 2019 ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials
08 Dec 2019 Molecular Partners Presents Updated Results of MP0250 in Patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology
08 Dec 2019 Grifols presents its latest Alzheimer's clinical trial data
06 Dec 2019 Fibriant Expands License Adding Recombinant Human (pro)thrombin to Existing Recombinant Fibrinogen Capability
05 Dec 2019 Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities
05 Dec 2019 Arecor Announces Positive Headline Results for the First Phase I Clinical Trial of AT247, a Novel Ultra Rapid Acting Formulation of Insulin
05 Dec 2019 Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
04 Dec 2019 Lannett Announces Positive Results From Human Clinical Trial Of Biosimilar Insulin Glargine Versus US Lantus®
04 Dec 2019 Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM
04 Dec 2019 Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
03 Dec 2019 INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study
26 Nov 2019 La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results
26 Nov 2019 Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines
21 Nov 2019 Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)
21 Nov 2019 Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock
19 Nov 2019 BioArctic Announces Results From Interim Analysis of the Phase 1/2 Study of SC0806 in Patients With Complete Spinal Cord Injury
13 Nov 2019 Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors
11 Nov 2019 Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
10 Nov 2019 Pieris Pharmaceuticals Presents Data Demonstrating Monotherapy Clinical Benefit with 4-1BB/HER2 Bispecific PRS-343 in Phase 1 Escalation Study at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
09 Nov 2019 Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week
09 Nov 2019 Codiak Presents New Preclinical Data for First-in-Class Exosome Therapeutic Candidates, exoIL-12 and exoSTING, Demonstrating Potent Anti-Tumor Activity
08 Nov 2019 Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
07 Nov 2019 Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease
06 Nov 2019 BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up